Although Risperdal was designed to treat schizophrenia, bipolar disorder, and autism, Johnson & Johnson reportedly encouraged doctors to prescribe it for the unapproved treatment of ADHD in children, resulting in hundreds of thousands of prescriptions. The company has been fined over $1.2 billion for this alleged false marketing.
Now, the company faces a new kind of lawsuit from thousands of patients, due to severe side effects like abnormal male breast growth and juvenile diabetes. Records show that Johnson & Johnson knew of these severe side effects but did not properly warn patients.
Attorneys have already helped nearly 500 Risperdal patients file lawsuits against the manufacturer. However, Johnson & Johnson has not admitted any fault. To know more regarding the same, you can also read Risperdal Male Breasts Lawsuits and Risperdal Breasts in Boys Lawsuit Information online.
Since the FDA has not issued a recall for the drug, compensation from litigation is among the few sources of help available.
Hundreds of young men and boys have filed Risperdal lawsuits seeking compensation from Johnson & Johnson for the pain and suffering they endured after developing gynecomastia. A growing body of research has shown a disturbing link between Risperdal and this condition, which results in the growth of male breast tissue.
Even more disturbing, Johnson & Johnson may have endeavored to conceal information that indicated Risperdal could cause male breast growth in boys in order to protect sales of the drug. Risperdal lawsuits also claim that the company illegally marketed this powerful antipsychotic drug to children. To know more about risperdal male breasts risks, one can also read this blog.
Risperdal was originally approved by the U.S. Food & Drug Administration (FDA) to treat adults with schizophrenia. But it was widely used off-label in children to treat bi-polar disorders, autism, and irritability, aggression, and behavior disorders. Since at least 1999, research has pointed to a link between Risperdal and male breast growth.
That year, as study was published that found that the condition could occur in patients treated with Risperdal in conjunction with Prozac. In 2006, researchers from Duke University reported that the risk of Risperdal gynecomastia was stronger compared to other atypical antipsychotics.